MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
MAXCYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.30+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $138.87M
- P/E (TTM)
- –
- Dividend yield
- –
MAXCYTE, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $4.10M | $3.64M | $4.15M | $3.95M | $5.27M | $5.32M | $5.80M | $5.20M | $4.74M | $5.36M | $4.49M | $3.90M | 56.4% | -22.2% |
| Licenses | $2.59M | $5.53M | $2.54M | $2.23M | $2.93M | $4.68M | $2.64M | $2.55M | $5.46M | $5.76M | – | – | 35.6% | -11.5% |
| Assay and other service revenue | $583.00K | $482.00K | $609.00K | $650.00K | $310.00K | $397.00K | – | $416.00K | $229.00K | $223.00K | – | – | 8.0% | +88.1% |
| Other | – | – | – | – | – | – | $258.00K | $416.00K | $229.00K | $223.00K | $263.00K | $258.00K | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $4.63M | $6.62M | $3.89M | $3.84M | $5.31M | $8.03M | $5.32M | $5.14M | $7.29M | $8.02M | – | – | 63.7% | -12.9% |
| Outside the United States | $2.64M | $3.04M | $3.41M | $2.99M | $3.19M | $2.36M | $3.37M | $3.02M | $3.14M | $3.32M | – | – | 36.3% | -17.3% |
From the segment and revenue-disaggregation notes of Maxcyte's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.